+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sinusitis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - By Product, Technology, Grade, Application, End-user and Region (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 220 Pages
  • July 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5852529
Sinusitis, a condition characterized by inflammation or swelling of the sinuses, has become a notable healthcare challenge, causing discomfort and decreased quality of life for patients. The condition, which often presents symptoms such as nasal congestion, facial pain, headaches, and decreased sense of smell, can be caused by various factors, including infections, allergies, and structural abnormalities. As the incidence of sinusitis continues to rise, the demand for effective treatment methods is also on the upswing, propelling the growth of the global sinusitis treatment market.

Focused R&D Activities Drive Momentum in Sinusitis Drug Discovery

The global healthcare community has taken note of the increasing incidence of chronic rhinosinusitis (CRC) and is actively engaging in focused research and development (R&D) activities to address the challenge. Healthcare organizations and pharmaceutical manufacturers are exploring newer and more effective diagnostic methods to detect chronic sinusitis at early stages. Additionally, nasal sprays are being developed to enhance drug delivery to hard-to-reach sinus cavities, offering improved treatment options for patients. As a result, the global sinusitis treatment market is poised for steady growth in the foreseeable future.

Increasing Demand for Antibiotics Bolsters Market Prospects

Antibiotics have been a groundbreaking medical discovery, revolutionizing the treatment of various diseases, including sinusitis. The rising demand for antibiotics as a primary treatment for sinusitis is driving substantial growth in the global sinusitis treatment market. Antibiotics act quickly to provide relief to patients, making them a preferred choice for acute sinusitis treatment in adults. Notable research and development efforts are also focused on enhancing antibiotic effectiveness and mitigating antibiotic resistance to further improve patient outcomes.

North America Leads the Way in Sinusitis Treatment Market

North America is at the forefront of the global sinusitis treatment market, driven by its higher healthcare awareness, expenditure, and a mature healthcare industry. The region's concentration of leading pharmaceutical companies and availability of over-the-counter sinusitis treatment drugs are creating a conducive environment for market growth. Key economies, such as the USA, play a significant role in propelling regional market expansion. Meanwhile, Asia Pacific is showing promising growth potential, driven by a rising population and increasing investments in the pharmaceutical industry.

Key Market Players

Prominent players in the global sinusitis treatment market include Stryker Corporation, AstraZeneca PLC, Medtronic PLC, Pfizer Inc., Novartis AG, Olympus Corporation, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Sanofi, Sun Pharmaceutical Industries Inc., GlaxoSmithKline, Mylan N.V., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Eli Lilly and Company, Amneal Pharmaceuticals LLC, Wockhardt, Bristol-Myers Squibb, and Hikma Pharmaceuticals PLC.

Table of Contents

1. Executive Summary
1.1. Global Sinusitis Treatment Market Outlook, 2018 - 2030 (US$ Million)
1.2. Global Sinusitis Treatment Market Incremental Opportunity, 2018 - 2030 (US$ Million)
1.3. Key Industry Trends
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.1.1. Driver 1
2.2.1.2. Driver 2
2.2.2. Restraints
2.2.2.1. Restraint 1
2.2.2.2. Restraint 2
2.2.3. Market Opportunities Matrix
2.3. Porters Five Forces Analysis
2.4. Regulatory Guidelines
2.5. Clinical Trials and Pipeline Overview
2.6. Covid-19 Impact Analysis
3. Global Sinusitis Treatment Market Outlook, 2018 - 2030
3.1. Global Sinusitis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Antihistamines
3.1.1.2. Corticosteroids
3.1.1.3. Analgesics
3.1.1.4. Antibiotics
3.1.1.5. Other
3.1.2. BPS Analysis/Market Attractiveness Analysis
4. Global Sinusitis Treatment Market Outlook, 2018 - 2030
4.1. Global Sinusitis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Chronic Sinusitis
4.1.1.2. Acute Sinusitis
4.1.1.3. Sub-Acute Sinusitis
4.1.2. BPS Analysis/Market Attractiveness Analysis
4.2. Global Sinusitis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Nasal
4.2.1.2. Oral
4.2.1.3. Injectable
4.2.1.4. Topical
4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. Global Sinusitis Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. North America
4.3.1.2. Europe
4.3.1.3. Asia Pacific
4.3.1.4. Rest of the World
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. North America Sinusitis Treatment Market Outlook, 2018 - 2030
5.1. North America Sinusitis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Antihistamines
5.1.1.2. Corticosteroids
5.1.1.3. Analgesics
5.1.1.4. Antibiotics
5.1.1.5. Other
5.1.2. BPS Analysis/Market Attractiveness Analysis
5.2. North America Sinusitis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Chronic Sinusitis
5.2.1.2. Acute Sinusitis
5.2.1.3. Sub-Acute Sinusitis
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. North America Sinusitis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Nasal
5.3.1.2. Oral
5.3.1.3. Injectable
5.3.1.4. Topical
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. North America Sinusitis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
5.4.1. Key Highlights
5.4.1.1. U.S.
5.4.1.2. Canada
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Europe Sinusitis Treatment Market Outlook, 2018 - 2030
6.1. Europe Sinusitis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Antihistamines
6.1.1.2. Corticosteroids
6.1.1.3. Analgesics
6.1.1.4. Antibiotics
6.1.1.5. Other
6.1.2. BPS Analysis/Market Attractiveness Analysis
6.2. Europe Sinusitis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Chronic Sinusitis
6.2.1.2. Acute Sinusitis
6.2.1.3. Sub-Acute Sinusitis
6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Europe Sinusitis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. Nasal
6.3.1.2. Oral
6.3.1.3. Injectable
6.3.1.4. Topical
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Europe Sinusitis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
6.4.1. Key Highlights
6.4.1.1. Germany
6.4.1.2. France
6.4.1.3. U.K.
6.4.1.4. Italy
6.4.1.5. Spain
6.4.1.6. Rest of Europe
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Asia Pacific Sinusitis Treatment Market Outlook, 2018 - 2030
7.1. Asia Pacific Sinusitis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Antihistamines
7.1.1.2. Corticosteroids
7.1.1.3. Analgesics
7.1.1.4. Antibiotics
7.1.1.5. Other
7.1.2. BPS Analysis/Market Attractiveness Analysis
7.2. Asia Pacific Sinusitis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Chronic Sinusitis
7.2.1.2. Acute Sinusitis
7.2.1.3. Sub-Acute Sinusitis
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Asia Pacific Sinusitis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. Nasal
7.3.1.2. Oral
7.3.1.3. Injectable
7.3.1.4. Topical
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Asia Pacific Sinusitis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
7.4.1. Key Highlights
7.4.1.1. China
7.4.1.2. Japan
7.4.1.3. India
7.4.1.4. South Korea
7.4.1.5. Australia & New Zealand
7.4.1.6. Rest of Asia Pacific
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Rest of the World Sinusitis Treatment Market Outlook, 2018 - 2030
8.1. Rest of the World Sinusitis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Antihistamines
8.1.1.2. Corticosteroids
8.1.1.3. Analgesics
8.1.1.4. Antibiotics
8.1.1.5. Other
8.1.2. BPS Analysis/Market Attractiveness Analysis
8.2. Rest of the World Sinusitis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Chronic Sinusitis
8.2.1.2. Acute Sinusitis
8.2.1.3. Sub-Acute Sinusitis
8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Rest of the World Sinusitis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. Nasal
8.3.1.2. Oral
8.3.1.3. Injectable
8.3.1.4. Topical
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Rest of the World Sinusitis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
8.4.1. Key Highlights
8.4.1.1. Latin America
8.4.1.2. Middle East & Africa
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis
9.2. Company Profiles
9.2.1. Pfizer, Inc.
9.2.1.1. Company Overview
9.2.1.2. Financial Overview
9.2.1.3. Treatment Type Portfolio
9.2.1.4. Recent Developments
*Above details will include, but not be limited to below list of companies based on availability
9.2.2. Abbott Laboratories
9.2.3. GSK plc
9.2.4. Novartis AG
9.2.5. Bayer AG
9.2.6. Fresenius Kabi AG
9.2.7. OptiNose US, Inc.
9.2.8. Lyra Therapeutics
9.2.9. Others
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Medtronic
  • Olympus
  • Stryker
  • Cipla
  • Dr. Reddys
  • GSK
  • OptiNose US, Inc.
  • Pfizer
  • Fresenius Kabi
  • Abbott
  • Bayer AG
  • Bristol-Myers Squibb
  • Amneal Pharmaceuticals LLC
  • Merck KGaA
  • Teva Pharmaceutical Industries
  • Novartis
  • Ondine Biomedical Inc.
  • Lyra Therapeutics, Inc.

Methodology

Loading
LOADING...